2022
Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference
Pashankar F, Hanley K, Lockley M, Stoneham S, Nucci MR, Reyes-Múgica M, Elishaev E, Vang R, Veneris J, Rytting H, Olson T, Hazard K, Covens A, Arora R, Billmire D, Al-Ibraheemi A, Ulbright TM, Frazier L, Hirsch MS. Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference. European Journal Of Cancer 2022, 173: 59-70. PMID: 35863107, DOI: 10.1016/j.ejca.2022.06.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultChildConsensus Development Conferences as TopicEndodermal Sinus TumorFemaleHumansNeoplasms, Germ Cell and EmbryonalOvarian NeoplasmsTeratomaConceptsOvarian immature teratomaImmature teratomaGerm cell tumor elementsSerum alpha-fetoproteinGerm cell tumorsYolk sac tumorSerum tumor biomarkersForm of sarcomaTherapeutic dilemmaSac tumorRare subtypeSomatic malignancyCell tumorsNeuroectodermal elementsNeuroectodermal componentConsensus conferenceAlpha-fetoproteinTumor elementsManagement dilemmaAdult womenPractice differencesTumor biomarkersTeratomaTumorsClinicopathologic conferenceUtility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group
Dicken B, Billmire D, Rich B, Hazard F, Nuño M, Krailo M, Fallahazad N, Pashankar F, Shaikh F, Frazier A. Utility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group. Gynecologic Oncology 2022, 166: 476-480. PMID: 35750503, PMCID: PMC9514449, DOI: 10.1016/j.ygyno.2022.06.013.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultChildFemaleFrozen SectionsHumansNeoplasms, Germ Cell and EmbryonalOvarian NeoplasmsParaffinRetrospective StudiesTesticular NeoplasmsConceptsIntra-operative frozen sectionOvarian germ cell tumorsGerm cell tumorsMalignant ovarian germ cell tumorsIntra-operative frozen section diagnosisFrozen section diagnosisCentral pathology reviewCell tumorsSurgical stagingAdolescent patientsFinal diagnosisFinal paraffin section diagnosisSection diagnosisFrozen sectionsParaffin section diagnosisOncology GroupPathology reviewCentral reviewOvarian germ cell malignanciesNonseminomatous germ cell tumorsGerm cell tumor componentsConfirmation of malignancyGerm cell malignanciesRecords of patientsChildren's Oncology Group
2020
Imaging Appearance of Nongerminoma Pediatric Ovarian Germ Cell Tumors Does Not Discriminate Benign from Malignant Histology
Billmire D, Dicken B, Rescorla F, Ross J, Piao J, Huang L, Krailo M, Pashankar F, Frazier L, Group C. Imaging Appearance of Nongerminoma Pediatric Ovarian Germ Cell Tumors Does Not Discriminate Benign from Malignant Histology. Journal Of Pediatric And Adolescent Gynecology 2020, 34: 383-386. PMID: 33316416, PMCID: PMC8096645, DOI: 10.1016/j.jpag.2020.11.014.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildChild, PreschoolDiagnostic ImagingFemaleHumansInfantNeoplasms, Germ Cell and EmbryonalOvarian NeoplasmsRetrospective StudiesTeratomaConceptsMalignant ovarian germ cell tumorsMalignant germ cell tumorsGerm cell tumorsOvarian germ cell tumorsCell tumorsOncology GroupMalignant histologyImaging appearancesExtracranial malignant germ cell tumorsNonseminomatous malignant germ cell tumorsOvarian malignant germ cell tumorsSolid appearanceComplete surgical stagingElement of teratomaPediatric ovarian neoplasmsPreoperative serum markersChildren's Oncology GroupPrimary ovarian tumorsYolk sac tumorYears of ageAssociated teratomaTeratoma elementsSurgical stagingMixed histologyMulticenter trialOutcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium
Shaikh F, Stark D, Fonseca A, Dang H, Xia C, Krailo M, Pashankar F, Rodriguez‐Galindo C, Olson TA, Nicholson JC, Murray MJ, Amatruda JF, Billmire D, Stoneham S, Frazier AL. Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium. Cancer 2020, 127: 193-202. PMID: 33079404, DOI: 10.1002/cncr.33273.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChildChild, PreschoolHumansInfantInfant, NewbornLymphatic MetastasisMaleMediastinal NeoplasmsNeoplasms, Germ Cell and EmbryonalProgression-Free SurvivalRetroperitoneal NeoplasmsRetrospective StudiesTesticular NeoplasmsYoung AdultConceptsMetastatic germ cell tumorsEvent-free survivalGerm cell tumorsCell tumorsRisk groupsYoung adultsAge groupsMale patientsAdolescent patientsAdolescent malesCox proportional hazards analysisMalignant germ cell tumorsIndividual patient databasePlatinum-based chemotherapyProportional hazards analysisYoung adult patientsClinical trial organizationsAdolescent age groupPediatric cooperative groupsTreatment of adolescentsDifferent age groupsAdult patientsClinical characteristicsEFS rateInclusion criteriaRe: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice
Pashankar F, Frazier AL. Re: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice. European Journal Of Cancer 2020, 130: 265-266. PMID: 32178968, DOI: 10.1016/j.ejca.2020.01.022.Peer-Reviewed Original ResearchMeSH KeywordsAdultChildFemaleHumansNeoplasms, Germ Cell and EmbryonalOvarian NeoplasmsRetrospective Studies
2019
α‐Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium
O’Neill A, Xia C, Krailo MD, Shaikh F, Pashankar FD, Billmire DF, Olson TA, Amatruda JF, Villaluna D, Huang L, Malogolowkin M, Rodriguez‐Galindo C, Frazier AL. α‐Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium. Cancer 2019, 125: 3649-3656. PMID: 31355926, DOI: 10.1002/cncr.32363.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAlpha-FetoproteinsBiomarkers, TumorChildChild, PreschoolDisease-Free SurvivalFemaleHumansInfantMaleNeoplasm Recurrence, LocalNeoplasms, Germ Cell and EmbryonalPrognosisRecurrenceRetrospective StudiesConceptsGerm cell tumorsChildren's Oncology GroupCell tumorsAFP declineCumulative incidenceOncology GroupOverall survivalPediatric patientsThree-year overall survivalFuture clinical trial designTumor marker declineStart of chemotherapyPredictors of outcomeRecognition of patientsClinical trial designYears of ageAdult patientsPoor prognosisSerum AFPMarker declineStratified analysisHigh riskTrial designPatientsEarly intensification
2018
Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group
Fonseca A, Xia C, Lorenzo AJ, Krailo M, Olson TA, Pashankar F, Malogolowkin MH, Amatruda JF, Billmire DF, Rodriguez-Galindo C, Frazier AL, Shaikh F. Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group. Journal Of Clinical Oncology 2018, 37: 396-402. PMID: 30576269, PMCID: PMC6553816, DOI: 10.1200/jco.18.00790.Peer-Reviewed Original ResearchConceptsMalignant germ cell tumorsTumor marker elevationNongerminomatous malignant germ cell tumorsAbnormal tumor markersGerm cell tumorsMarker elevationTumor markersRelapse surveillanceOncology GroupInitial diagnosisCell tumorsChildren's Oncology GroupDetection of relapseSingle-arm trialNormal tumor markersCase report formsAbnormal imagingCentral reviewMarker levelsPathology reportsRelapsePatientsPhase IIIReport formsComplete dataProtocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours
Lawrence NJ, Chan H, Toner G, Stockler MR, Martin A, Yip S, Wong N, Yeung A, Mazhar D, Pashankar F, Frazier L, McDermott R, Walker R, Tan H, Davis ID, Grimison P, on behalf of ANZUP. Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours. BMC Cancer 2018, 18: 854. PMID: 30157803, PMCID: PMC6114870, DOI: 10.1186/s12885-018-4745-3.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCisplatinClinical ProtocolsClinical Trials, Phase III as TopicEtoposideFemaleHumansInfantInfant, NewbornMaleMulticenter Studies as TopicNeoplasms, Germ Cell and EmbryonalRandomized Controlled Trials as TopicResearch DesignYoung AdultConceptsPoor-risk metastatic germ cell tumoursMetastatic germ cell tumorsGerm cell tumorsStandard BEP chemotherapyFirst-line chemotherapyCell tumorsLine chemotherapyBEP chemotherapyCure rateClinical trialsPoor-risk germ cell tumorsMulticentre phase 2 trialRandomised phase 3 trialStandard first-line treatmentPhase 3 clinical trialsComplete response rateFirst-line treatmentPhase 2 trialPhase 3 trialProgression-free survivalHealth-related qualityPediatric age groupFemale participantsInternational multicentreStandard BEPIs carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?
Shah R, Xia C, Krailo M, Amatruda JF, Arul SG, Billmire DF, Brady WE, Covens A, Gershenson DM, Hale JP, Hurteau J, Murray MJ, Nicholson JC, Olson TA, Pashankar F, Rodriguez-Galindo C, Shaikh F, Stark D, Frazier AL, Stoneham S. Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults? Gynecologic Oncology 2018, 150: 253-260. PMID: 29884437, DOI: 10.1016/j.ygyno.2018.05.025.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsCarboplatinChildCisplatinClinical Trials as TopicDysgerminomaFemaleHumansNeoplasm StagingNeoplasms, Germ Cell and EmbryonalOvarian NeoplasmsPrognosisYoung AdultConceptsCisplatin-based chemotherapyClinical trial organizationsGerm cell tumorsFive-year event-free survivalMalignant ovarian germ cell tumorsOvarian germ cell tumorsAge groupsCarboplatin-based chemotherapyTreatment-related toxicityEvent-free survivalEligible patientsExcellent OSMetastatic diseaseOverall survivalClinical outcomesFrontline treatmentSurvival outcomesMean agePeak incidenceCell tumorsDysgerminomaChemotherapyPatientsTrials OrganizationCarboplatinComparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium
Frazier AL, Stoneham S, Rodriguez-Galindo C, Dang H, Xia C, Olson TA, Murray MJ, Amatruda JF, Shaikh F, Pashankar F, Billmire D, Krailo M, Stark D, Brougham MFH, Nicholson JC, Hale JP. Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium. European Journal Of Cancer 2018, 98: 30-37. PMID: 29859339, DOI: 10.1016/j.ejca.2018.03.004.Peer-Reviewed Original ResearchConceptsChildren's Oncology GroupEvent-free survivalOncology GroupClinical trialsGerm cell tumor patientsCarboplatin-based regimensCisplatin-based regimensParametric cure modelsLeukemia groupTumor patientsStandard riskChildren's CancerRegimensCancerRiskTrialsGroupCure modelPatientsCarboplatinInternational ConsortiumCisplatinTreatment of refractory germ cell tumors in children with paclitaxel, ifosfamide, and carboplatin: A report from the Children's Oncology Group AGCT0521 study
Pashankar F, Frazier AL, Krailo M, Xia C, Pappo AS, Malogolowkin M, Olson TA, Rodriguez‐Galindo C. Treatment of refractory germ cell tumors in children with paclitaxel, ifosfamide, and carboplatin: A report from the Children's Oncology Group AGCT0521 study. Pediatric Blood & Cancer 2018, 65: e27111. PMID: 29697191, PMCID: PMC6019185, DOI: 10.1002/pbc.27111.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarboplatinChildChild, PreschoolFemaleHumansIfosfamideInfantMaleNeoplasms, Germ Cell and EmbryonalPaclitaxelSalvage TherapyConceptsMalignant germ cell tumorsPediatric malignant germ cell tumorsGerm cell tumorsOncology GroupCell tumorsMarker declineRefractory germ cell tumorsHigh-dose chemotherapyPhase II trialChildren's Oncology GroupGroup of patientsLong-term toxicityRECIST responseSalvage therapyStable diseaseTIP regimenII trialRECIST criteriaElevated markersPartial responseProgressive diseaseStandard therapyAdditional administrationTumor markersPatients
2017
Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 study
Dicken BJ, Billmire DF, Krailo M, Xia C, Shaikh F, Cullen JW, Olson TA, Pashankar F, Malogolowkin MH, Amatruda JF, Rescorla FJ, Egler RA, Ross JH, Rodriguez‐Galindo C, Frazier AL. Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 study. Pediatric Blood & Cancer 2017, 65 PMID: 29286555, PMCID: PMC6219870, DOI: 10.1002/pbc.26913.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultChildChild, PreschoolDisease-Free SurvivalFemaleGonadal DysgenesisHumansInfantInfant, NewbornNeoplasms, Germ Cell and EmbryonalOvarian NeoplasmsSurvival RateConceptsOvarian germ cell tumorsMalignant ovarian germ cell tumorsGerm cell tumorsEvent-free survivalNon-GD patientsOverall survivalGonadal dysgenesisMalignant germ cell tumorsAggressive chemotherapy regimenHigh-risk groupNondysgerminomatous tumorsChemotherapy regimenPure dysgerminomaPediatric patientsSac tumorBilateral gonadectomyCell tumorsWorse outcomesEmbryonal carcinomaPatientsStreak ovariesDysgenetic gonadsTumorsY chromosome materialGonadoblastomaReduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group
Shaikh F, Cullen JW, Olson TA, Pashankar F, Malogolowkin MH, Amatruda JF, Villaluna D, Krailo M, Billmire DF, Rescorla FJ, Egler RA, Dicken BJ, Ross JH, Schlatter M, Rodriguez-Galindo C, Frazier AL. Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group. Journal Of Clinical Oncology 2017, 35: jco.2016.67.654. PMID: 28240974, PMCID: PMC5455599, DOI: 10.1200/jco.2016.67.6544.Peer-Reviewed Original ResearchConceptsMalignant germ cell tumorsEvent-free survivalCycles of PEBEFS ratesGerm cell tumorsOncology GroupCell tumorsExtracranial malignant germ cell tumorsReduction of therapyChildren's Oncology GroupSingle-arm trialLow-stage tumorsHigh-stage tumorsAdministration of cisplatinEligible patientsComparable patientsHistorical cohortPatientsTumorsStatistical significanceComparable childrenPhase 3ChildrenP-valueOne-sided p-value
2016
Paediatric extracranial germ-cell tumours
Shaikh F, Murray MJ, Amatruda JF, Coleman N, Nicholson JC, Hale JP, Pashankar F, Stoneham SJ, Poynter JN, Olson TA, Billmire DF, Stark D, Rodriguez-Galindo C, Frazier AL. Paediatric extracranial germ-cell tumours. The Lancet Oncology 2016, 17: e149-e162. PMID: 27300675, DOI: 10.1016/s1470-2045(15)00545-8.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBiomarkers, TumorChildFemaleHumansMaleNeoplasms, Germ Cell and EmbryonalOvarian NeoplasmsPediatricsSurvivorsTesticular NeoplasmsConceptsGerm cell tumorsPediatric extracranial germ cell tumorExtracranial germ cell tumorsPediatric germ cell tumorsSignificant long-term toxicityPoor-risk patientsLow-risk patientsPlatinum-resistant diseaseGroup of patientsHigh tumor markersEvidence-based careRisk stratification systemLong-term toxicityCooperative Research GroupExtragonadal tumorsRisk stratificationFuture trialsClinical behaviorPatient outcomesClinical dataAdult diseaseWide age rangeTumor markersTreatment approachesPatients
2015
Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration
Olson TA, Murray MJ, Rodriguez-Galindo C, Nicholson JC, Billmire DF, Krailo MD, Dang HM, Amatruda JF, Thornton CM, Arul GS, Stoneham SJ, Pashankar F, Stark D, Shaikh F, Gershenson DM, Covens A, Hurteau J, Stenning SP, Feldman DR, Grimison PS, Huddart RA, Sweeney C, Powles T, Lopes LF, dos Santos Agular S, Chinnaswamy G, Khaleel S, Abouelnaga S, Hale JP, Frazier AL. Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration. Journal Of Clinical Oncology 2015, 33: 3018-3028. PMID: 26304902, PMCID: PMC4979195, DOI: 10.1200/jco.2014.60.5337.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge of OnsetChildCooperative BehaviorDiffusion of InnovationFemaleHistory, 20th CenturyHistory, 21st CenturyHumansInterdisciplinary CommunicationInternational CooperationMaleMedical OncologyNeoplasms, Germ Cell and EmbryonalPediatricsSurvivorsTime FactorsTreatment OutcomeYoung AdultConceptsGerm cell tumorsPrimary tumor siteCell tumorsExtracranial malignant germ cell tumorsExtracranial germ cell tumorsTumor siteMalignant germ cell tumorsSignificant long-term morbidityDifferent risk stratificationLong-term morbidityPlatinum-based chemotherapyPediatric cancer patientsTreatment-related effectsDifferent cooperative groupsCisplatin dosingVariety of specialistsMedical oncologistsGynecologic oncologistsRisk stratificationTherapeutic dilemmaHistologic featuresPediatric oncologistsExcellent outcomesStaging systemCancer patients
2014
Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors Based on 25 Years of Clinical Trial Data From the United Kingdom and United States
Frazier AL, Hale JP, Rodriguez-Galindo C, Dang H, Olson T, Murray MJ, Amatruda JF, Thornton C, Arul GS, Billmire D, Shaikh F, Pashankar F, Stoneham S, Krailo M, Nicholson JC. Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors Based on 25 Years of Clinical Trial Data From the United Kingdom and United States. Journal Of Clinical Oncology 2014, 33: 195-201. PMID: 25452439, PMCID: PMC4279239, DOI: 10.1200/jco.2014.58.3369.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge FactorsAlpha-FetoproteinsBiomarkers, TumorChildChild, PreschoolClinical Trials as TopicDisease-Free SurvivalEndodermal Sinus TumorEvidence-Based MedicineFemaleHumansMaleModels, StatisticalNeoplasm StagingNeoplasms, Germ Cell and EmbryonalPredictive Value of TestsPrognosisRetrospective StudiesRisk AssessmentRisk FactorsUnited KingdomUnited StatesConceptsGerm cell tumorsYolk sac tumorPediatric germ cell tumorsClinical trial dataAlpha-fetoproteinTumor siteOncology GroupCell tumorsMalignant pediatric germ cell tumorsPediatric extracranial germ cell tumorLong-term disease-free survivalEvidence-based risk stratificationExtracranial germ cell tumorsTrial dataPure yolk sac tumorPoor-risk groupStage IV diseaseDisease-free survivalPercentage of patientsChildren's Oncology GroupElevated alpha-fetoproteinPlatinum-based therapyClinical trial organizationsParametric cure modelsLeukemia groupSurveillance After Initial Surgery for Pediatric and Adolescent Girls With Stage I Ovarian Germ Cell Tumors: Report From the Children's Oncology Group
Billmire DF, Cullen JW, Rescorla FJ, Davis M, Schlatter MG, Olson TA, Malogolowkin MH, Pashankar F, Villaluna D, Krailo M, Egler RA, Rodriguez-Galindo C, Frazier AL. Surveillance After Initial Surgery for Pediatric and Adolescent Girls With Stage I Ovarian Germ Cell Tumors: Report From the Children's Oncology Group. Journal Of Clinical Oncology 2014, 32: 465-470. PMID: 24395845, PMCID: PMC4876316, DOI: 10.1200/jco.2013.51.1006.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAlpha-FetoproteinsAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCisplatinDisease-Free SurvivalEtoposideFemaleHumansInfantInfant, NewbornKaplan-Meier EstimateNeoplasm Recurrence, LocalNeoplasm StagingNeoplasm, ResidualNeoplasms, Germ Cell and EmbryonalOvarian NeoplasmsRadiographyRisk FactorsSalvage TherapyTime FactorsTreatment OutcomeConceptsMalignant ovarian germ cell tumorsStage I malignant ovarian germ cell tumorsOvarian germ cell tumorsEvent-free survivalGerm cell tumorsOverall survivalAlpha-fetoproteinRecurrent diseaseOncology GroupCell tumorsSuccessful Salvage ChemotherapyTumor marker elevationPercent of patientsKaplan-Meier methodChildren's Oncology GroupSerum tumor markersPredominant histologySalvage chemotherapyInitial surgeryMarker elevationMetastatic diseaseSurgical resectionMedian timeYolk sacTumor markers